Bayesian Capital Management LP Invests $199,000 in Schrödinger, Inc. (NASDAQ:SDGR)

Bayesian Capital Management LP acquired a new stake in Schrödinger, Inc. (NASDAQ:SDGR) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,300 shares of the company’s stock, valued at approximately $199,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC lifted its stake in shares of Schrödinger by 421.6% in the third quarter. Barclays PLC now owns 107,554 shares of the company’s stock worth $1,995,000 after buying an additional 86,933 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Schrödinger by 3.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 122,702 shares of the company’s stock worth $2,276,000 after acquiring an additional 4,403 shares during the period. GAMMA Investing LLC lifted its position in Schrödinger by 87.5% during the 4th quarter. GAMMA Investing LLC now owns 2,796 shares of the company’s stock worth $54,000 after acquiring an additional 1,305 shares during the last quarter. Avanza Fonder AB bought a new stake in Schrödinger during the fourth quarter valued at about $577,000. Finally, Geneos Wealth Management Inc. grew its position in shares of Schrödinger by 15.4% in the fourth quarter. Geneos Wealth Management Inc. now owns 59,996 shares of the company’s stock valued at $1,157,000 after purchasing an additional 8,021 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on SDGR. Piper Sandler decreased their target price on Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Thursday, February 27th. KeyCorp increased their price objective on Schrödinger from $30.00 to $32.00 and gave the company an “overweight” rating in a research report on Wednesday, April 16th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $32.80.

Insider Buying and Selling

In related news, insider Karen Akinsanya sold 16,723 shares of the firm’s stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $25.09, for a total transaction of $419,580.07. Following the completion of the transaction, the insider now owns 15,625 shares in the company, valued at $392,031.25. This trade represents a 51.70 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Geoffrey Craig Porges sold 5,491 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $21.76, for a total value of $119,484.16. Following the transaction, the chief financial officer now owns 27,544 shares of the company’s stock, valued at $599,357.44. This represents a 16.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 8.60% of the company’s stock.

Schrödinger Trading Up 0.6 %

Shares of NASDAQ:SDGR opened at $23.86 on Friday. The firm has a market capitalization of $1.74 billion, a PE ratio of -10.20 and a beta of 1.84. Schrödinger, Inc. has a 1-year low of $16.60 and a 1-year high of $28.47. The business’s 50 day moving average is $22.57 and its 200-day moving average is $21.73.

Schrödinger (NASDAQ:SDGR) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.01). Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The business had revenue of $59.55 million for the quarter, compared to analyst estimates of $54.60 million. During the same quarter in the prior year, the firm earned ($0.86) EPS. The firm’s quarterly revenue was up 62.7% on a year-over-year basis. On average, sell-side analysts predict that Schrödinger, Inc. will post -2.37 EPS for the current year.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.